An Open Label Study Assessing the Safety and Tolerability of SB206 in Japanese subjects with Molluscum Contagiosum
- Conditions
- Molluscum contagiosum
- Registration Number
- JPRN-jRCT2031230123
- Lead Sponsor
- Yoshiyuki Kaneko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Japanese patients with molluscum contagiosum aged 2 years or older and in good general health;
- Patients who are able to understand and follow study instructions or who have support from the parent or legal guardian;
- Patients who have a documented informed consent from voluntary signed by subject or a representative (parent or legal guardian) who received full explanations regarding the objectives and details of the study and the study drug.
- Patients who have molluscum contagiosum only in periocular area;
- Patients who have received any treatment for molluscum contagiosum during the 14 days prior to Baseline;
- Patients who are suspected to be immunosuppressed or have immunodeficiency disorder, or are on immunosuppressive treatment;
- Patients who have history or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and Tolerability
- Secondary Outcome Measures
Name Time Method